Sales of Cannabis Products to Grow as California's Recreational Laws go Live

NEW YORK, January 3, 2018 /PRNewswire/ --

According to a report by New Frontier Data, the legal cannabis market was worth $6.6 billion in 2016 and is forecast to grow to $24.1 billion by 2025 with a compound annual growth rate of 16 percent. The medical cannabis market was worth $4.7 billion in 2016 and is expected to grow to $13.3 billion by 2025. Sales of products for reactional use during the same period are projected to grow at a 21 percent CAGR, from $1.9 billion to $10.9 billion. Now, that California's new recreational cannabis laws went into effect on January 1st, 2018, growth of the legal cannabis industry will reaccelerate. California is the largest market for legal cannabis, and as the most populous state in the country it will play a major role in the future of the industry. FinCanna Capital Corp. (CSE: CALI), Emerald Health Therapeutics, Inc. (OTC: EMHTF), Namaste Technologies Inc. (OTC: NXTTF), iAnthus Capital Holdings, Inc. (OTC: ITHUF), Lifestyle Delivery System Inc. (OTC: LDSYF)

Arcview Market Research Arcview editor-in-chief, Tom Adams, explained, "Our data shows positive indicators across the board for the legal cannabis industry, in North America and around the globe... That's nothing compared to what we can expect in 2018 and beyond from Nevada's tourism, and California and Canada planning to launch adult-use sales in 2018." Focusing on the value of the industry in California, a report by Fortune indicates that, "in order to collect $1 billion a year in taxes, the state will need to reach a projected $7 billion in annual legal recreational cannabis sales."

FinCanna Capital Corp. (CSE: CALI) listed on the Canadian Securities Exchange under the trading symbol "CALI". On January 2nd the company announced, "that as of January 1, 2018, under the Medical and Adult Use Cannabis Regulation and Safety Act ("MAUCRSA"), cannabis in California will be regulated by various state agencies.

Following Proposition 215 which allowed a system for legal medical cannabis under what is commonly referred to as "collective law" - under MAUCRSA, a full framework of state licensure now exists which includes taxation and comprehensive regulations for cultivation, manufacturing, distribution, testing, and retail. The state of California reports that revenue from taxation will be allocated to research, treatment, enforcement, amongst other initiatives [ ]  . [ ]

New state licensing and regulations legitimize the billion-dollar cannabis industry in California. FinCanna believes top-tier Companies with state licenses are positioned to prosper and represent royalty investment opportunities in which the Company is targeting. The regulations are expected to change existing supply/demand dynamics and generate significant tax revenue for the state of California, the single largest medical cannabis market in the United States. To operate legally in California after January 1, 2018, every stage of the supply chain in California must be state-licensed therefore certain amounts of existing production will no longer be legally eligible for retail sale in California.

Andriyko Herchak, President and CEO of FinCanna states, "We are in strong support of these new laws which provide a clear regulatory framework, allowing companies to operate ethically and legally in the state of California."

New state laws will also require stringent product management standards for the cannabis industry systems to establish industry standards regarding testing, packaging and labeling. Regulations also require a fully transparent seed-to-sale tracking system through the newly created State Regulatory Agency - CalCannabis Cultivation Licensing within the California Department of Food and Agriculture (CDFA). Implementation of this "track and trace" system are designed to ensure accountability for all stakeholders helping eliminate non-compliant products being sold.

FinCanna supports these new measures in California and stands behind this clearer, more regulated market as set out by the Bureau of Cannabis Control, the Manufactured Cannabis Safety Branch in the Department of Public Health and the CalCannabis Cultivation Licensing division, all as set out under MAUCRSA."

Emerald Health Therapeutics, Inc. (OTCQX: EMHTF) operates through Emerald Health Botanicals Inc., a wholly owned subsidiary and Licensed Producer under Canada's Access to Cannabis for Medical Purposes Regulations. On December 15, 2017, the company's subsidiary Northern Vine Labs announced that Health Canada has approved an amendment to the Company's dealer's license. The license amendment provides the Company the ability to transport, deliver and sell product to other Licensed Dealers, authorized persons under the Controlled Drug and Substance Act, and Licensed Producers. Along with the Company's already authorized activities for analytical testing, extraction, and import/export, this amendment also allows Northern Vine Labs to broaden its business opportunities through the production and sale of downstream cannabis products.

Namaste Technologies Inc. (OTCQB: NXTTF) is an emerging leader in vaporizer and accessories space. On December 27, 2017, the company announced that it has signed a Letter of Intent ("LOI") with BRLEV AGRICULTURAL CROPS LTD. ("BRLEV"), through its wholly owned subsidiary, Cannmart Inc. ("CannMart"), whereby BRLEV will supply CannMart with high quality medical cannabis, to be imported by CannMart from Israel and offered in the Company's online marketplace. BRLEV is Israel's largest licensed producer of medical cannabis, with over 40 years of experience in commercial agricultural production and export. BRLEV will work with Namaste to export medical cannabis to the Canadian market, which will fall under Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR") guidelines. The LOI and the proposed medical cannabis supply agreement highlight Namaste's intentions of becoming Canada's leading online retailer for medical cannabis products, by focusing on importation of high quality medical cannabis from industry-leading countries like Israel.

iAnthus Capital Holdings, Inc. (OTCQB: ITHUF) provides investors diversified exposure to best-in-class licensed cannabis cultivators, processors and dispensaries throughout the United States. Recently, the company announced that Mayflower Medicinals, Inc. received its final certificate of registration and certificate of occupancy from Massachusetts regulators and local officials on December 28, 2017 to begin cannabis cultivation and production operations at its facility in Holliston, Massachusetts. Mayflower is a non-profit Massachusetts corporation that has received two provisional licenses to operate Registered Marijuana Dispensaries in Massachusetts, with a third RMD application pending before the Massachusetts Department of Public Health.

Lifestyle Delivery System Inc. (OTCQB: LDSYF) is a licensed, state-compliant vertically integrated cannabis related company. On December 22, 2017, the company announced that on December 21, 2017, the Manufactured Cannabis Safety Branch of the California Department of Public Health has issued CSPA Group, Inc. a Temporary Category M Type 7 Manufacturing with Volatile Solvents License which will be effective January 1, 2018 through April 30, 2018. During this time, the California Department of Public Health will review CSPA's application and corresponding municipal permits and documentation for a permanent license.

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on  (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, expects to be compensated five thousand dollars for financial news dissemination and PR services by fincanna capital corp. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:


        Media Contact: